FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

PDL sells off drugs as it counters harsh criticism

Tools

PDL BioPharma has auctioned off two marketed drugs and two experimental therapies as it restructures in the face of some severe criticism over how it's been managed. PDL was hammered last year for losing $130 million and moving into a swanky new headquarters building in Redwood City, CA. As a result, it started auctioning off assets. In this new deal, EKR Therapeutics will buy the hypertension drug Cardene and the heart therapy retavase along with an experimental therapy for heart failure and a new formulation of Cardene.

- see the release for more

Related Articles:
PDL BioPharma puts out 'for sale' sign. Report
In last act, PDL chief takes out the axe. Report
PDL chief resigns in wake of investor wrangle. Report
Biotech CEOs face rising fury of angry investors. Report
PDL BioPharma rises on shareholder complaint. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about experimental therapy   heart disease   assets   hypertension   biotech investing   Cardene   Retavase